- Home
- AIRI vs MTVA Comparison
AIRI vs MTVA Comparison
Compare AIRI & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- MTVA
- Stock Information
- Founded
- AIRI 1979
- MTVA 2014
- Country
- AIRI United States
- MTVA United States
- Employees
- AIRI N/A
- MTVA N/A
- Industry
- AIRI Military/Government/Technical
- MTVA
- Sector
- AIRI Industrials
- MTVA
- Exchange
- AIRI Nasdaq
- MTVA NYSE
- Market Cap
- AIRI 15.0M
- MTVA 16.8M
- IPO Year
- AIRI N/A
- MTVA N/A
- Fundamental
- Price
- AIRI $3.90
- MTVA $1.60
- Analyst Decision
- AIRI
- MTVA Strong Buy
- Analyst Count
- AIRI 0
- MTVA 1
- Target Price
- AIRI N/A
- MTVA $12.00
- AVG Volume (30 Days)
- AIRI 27.9K
- MTVA 23.0K
- Earning Date
- AIRI 03-31-2025
- MTVA 03-27-2025
- Dividend Yield
- AIRI N/A
- MTVA N/A
- EPS Growth
- AIRI N/A
- MTVA N/A
- EPS
- AIRI N/A
- MTVA N/A
- Revenue
- AIRI $53,657,000.00
- MTVA N/A
- Revenue This Year
- AIRI $7.29
- MTVA N/A
- Revenue Next Year
- AIRI $1.50
- MTVA N/A
- P/E Ratio
- AIRI N/A
- MTVA N/A
- Revenue Growth
- AIRI 3.31
- MTVA N/A
- 52 Week Low
- AIRI $3.03
- MTVA $1.51
- 52 Week High
- AIRI $9.44
- MTVA $6.75
- Technical
- Relative Strength Index (RSI)
- AIRI 28.76
- MTVA N/A
- Support Level
- AIRI $4.19
- MTVA N/A
- Resistance Level
- AIRI $4.25
- MTVA N/A
- Average True Range (ATR)
- AIRI 0.11
- MTVA 0.00
- MACD
- AIRI -0.03
- MTVA 0.00
- Stochastic Oscillator
- AIRI 23.81
- MTVA 0.00
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.